Medipattern narrows losses in Q1

Medipattern has posted a net loss of  CAD $717,288 (U.S. $678,895) for the first quarter of fiscal 2010, which ended Sept. 30. Despite the loss, it represented a 35 percent improvement over the CAD1.1 million ($1 million U.S.) loss reported during the same period last year.

Revenue for the Toronto, Ontario-based company was CAD2.12 million ($2.01 million U.S.) in the first quarter compared to approximately CAD76,000 ($72,000 U.S.) posted in the first quarter last year.

Medipattern's CEO Jeff Collins said the drop in earnings was due to timing issues connected with a shift from a traditional licensing model to an annuity model. "As an inducement under the long-term contract, we give customers a grace period before payments begin, which impacted our results in the quarter," Collins said.

Total expenses for the first quarter of the 2010 fiscal year declined 39 percent to CAD720,000 ($680,000 U.S.) from CAD1.18 million ($1.12 million U.S.) in the same period last year, mostly as a result of reduced sales and marketing costs, research & development and administrative costs.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.